EPCAM and breast carcinoma: Using RT-PCR, Aktas et al. [3] reported that 62% of CTCs were positive for at least one EMT marker, whereas CTCs isolated by CELLectionTMDynabeads coated with the monoclonal antibody toward EpCAM were negative for both keratins and CD45 [4], but positive for vimentin and fibronectin in 34% of patients with breast cancer.